The Mires of Research Evaluation

All organizations who fund and conduct scientific research are increasingly "under the gun" to better evaluate the performance of their programs. Scientific research is supported by two major sponsors; the federal government funds most basic research and industry supports the more applied research. These sponsors have organizational goals and obligations to their stakeholders. They must account for their expenditures and must justify these investment decisions. How to do so in a viable yet accep

Written byEliezer Geisler
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

The key issue in research evaluation is the combination of the scientific process being such a complex phenomenon, and our constant desire to quantify its outcomes. This has led to the use of multiple indicators, such as counts of publications, counts of citations, and peer-review. The vast majority of the problems discussed by Phelan, Perry, and other writers are primarily due to the issues inherent in measuring complex phenomena with an array of indicators. Products from research include a wide variety of outcomes, from "nuggets" of knowledge to an array of ideas, concepts, methods, techniques, and explanations. Downstream outcomes include patents, prototypes, and design criteria. Certain metrics (such as bibliometrics) can only capture a portion of these outcomes. Moreover, these outcomes (or products) are differentially prioritized by performers and sponsors and create inherent conflicts.

Given that only a fraction of research is documented and captured by bibliometric measures, some, if ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies